COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience

Hematologic parameters in patients with COVID‐19 infection

(2020) Bingwen Eugene Fan et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

(2020) Wenhua Liang et al.   LANCET ONCOLOGY

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

(2020) Melissa Bersanelli   Immunotherapy

Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic

(2020) Giuseppe Curigliano et al.   BREAST

A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy

(2020) Albert Grinshpun et al.   Frontiers in Oncology

Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors

(2019) Johannes Ettl   Breast Care

Aging and the immune system: An overview

(2018) Amir A. Sadighi Akha   JOURNAL OF IMMUNOLOGICAL METHODS

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis

(2017) Loay Kassem et al.   Breast Cancer

Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies

(2015) W. Hu et al.   CLINICAL CANCER RESEARCH

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

(2015) Peter Savas et al.   Nature Reviews Clinical Oncology